Extended-release Guanfacine Hydrochloride

DRUG4 trials

Sponsors

Shire

Conditions

Attention Deficit Hyperactivity DisorderAttention-Deficit/Hyperactivity DisorderAttention-deficit/Hyperactivity Disorder

Phase 3

Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)

CompletedNCT00997984

ShireAttention-Deficit/Hyperactivity Disorder

Start: 2009-11-17End: 2010-10-09Updated: 2021-06-08

Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

CompletedNCT01081132

ShireAttention-Deficit/Hyperactivity Disorder

Start: 2011-09-19End: 2013-05-16Updated: 2021-06-28

Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

CompletedNCT01081145

ShireAttention-deficit/Hyperactivity Disorder

Start: 2010-05-11End: 2013-06-03Updated: 2021-06-14

Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

CompletedNCT01244490

ShireAttention Deficit Hyperactivity Disorder

Start: 2011-01-17End: 2013-05-01Updated: 2021-07-02

Related Papers

Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study.

2016-02-1225 citations

Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.

2015-11-0118 citations

A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.

2015-09-1539 citations

EPA-0666 – Long-term maintenance of efficacy of extended-release guanfacine hydrochloride (GXR) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD): double-blind, placebo-controlled, multicentre, phase 3 randomized withdrawal study

European Psychiatry2014-01-015 citations

EPA-0685 – Guanfacine XR (GXR) for children and adolescents with attention-deficit/hyperactivity disorder (ADHD): phase 3, randomized, double-blind, multicenter, placebo- and active-reference study

European Psychiatry2014-01-013 citations